Advanced search
Publication Cover
OncoImmunology Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,159
Views
9
CrossRef citations to date
0
Altmetric
Original Research

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy

Xiaofei Lia Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Mingjie Lua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Manman Yuanb State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaView further author information
,
Jing Yeb State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaView further author information
,
Wei Zhanga Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Lingyan Xua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Xiaohan Wua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Bingqing Huia Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Yuchen Yanga Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
,
Bin Weic Department of Oncology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, Jiangsu, ChinaView further author information
,
Ciliang Guod Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaView further author information
,
Min Weid Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaView further author information
,
Jie Dongd Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
,
Xingxin Wub State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
&
Yanhong Gua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2118210 | Received 21 Nov 2021, Accepted 24 Aug 2022, Published online: 31 Aug 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.